Jonathan Yen-Wen Yu, serving as the Chief Operating Officer for Disc Medicine, Inc. (NASDAQ: IRON), finalized a transaction involving the sale of 9,700 shares of the company's common equity on June 22, 2026. The total value of this disposition reached $704,795. The shares were executed at a price range of $72.50 to $72.68 per share. This execution price sits slightly above the stock's reported value of $70.37 at the time of the transaction. The sale was carried out in accordance with a Rule 10b5-1 trading plan that was originally adopted on March 17, 2026.
The timing of this sale warrants attention as Disc Medicine shares have demonstrated significant movement over the past year, delivering a return of 30.52%. Current trading data suggests the stock is positioned above its InvestingPro Fair Value estimate, a metric that may imply the valuation is elevated relative to intrinsic metrics. Market data provided by InvestingPro Tips indicates the stock exhibits considerable volatility, characterized by a beta of 2.1.
Before the shares were sold, Mr. Yu acquired 9,700 shares of common stock on the same day, June 22, 2026. This acquisition was facilitated through the exercise of stock options at a strike price of $13.50 per share, resulting in a total cost of $130,950. These options were granted as part of an award designed to vest in 48 equal monthly installments following December 29, 2022, contingent upon his continued service with the company. This acquisition was also integrated into the same Rule 10b5-1 trading plan.
Following the completion of these transactions, Mr. Yu's direct holding in Disc Medicine, Inc. common stock stands at 54,324 shares. Additionally, he maintains a position in 24,147 derivative shares in the form of stock options. These options carry an exercise price of $13.50 and are set to expire on December 28, 2032.
In parallel with executive activity, Disc Medicine has been active in clinical and regulatory arenas. The company recently presented updated clinical trial data for two investigational treatments at the European Hematology Association Annual Meeting in Stockholm. The RALLY-MF trial focused on DISC-0974, which enrolled 61 adult patients suffering from myelofibrosis and anemia. The responder analysis included data from 50 patients, showing promising results.
Furthermore, Disc Medicine completed a Type A meeting with the U.S. Food and Drug Administration regarding bitopertin. This meeting addressed the Complete Response Letter for erythropoietic protoporphyria. The FDA indicated that if the ongoing Phase 3 APOLLO study achieves success, it could support a traditional approval pathway. A response regarding this matter is expected by the end of 2026.
Stifel reiterated a Buy rating on Disc Medicine following the presentation of Phase 2 RALLY-MF trial data. The firm highlighted the drug's efficacy regardless of baseline anemia severity. Disc Medicine also launched an expanded access program for bitopertin in the United States for eligible patients with erythropoietic protoporphyria and X-linked protoporphyria. This program provides access to bitopertin prior to regulatory approval for patients who lack satisfactory therapeutic alternatives.
Additionally, Disc Medicine announced plans to present data from its RALLY-MF Phase 2 trial at the American Society of Clinical Oncology Annual Meeting. This presentation will focus on anemia response rates in the myelofibrosis population. The stock closed at $70.37, down $0.11 or 0.16% during regular trading hours. After-hours trading showed a value of $70.37 at 17:44:22.